

1 October 2018

NSX Announcement

UPDATE ON SPONSORED RESEARCH AGREEMENT WITH COLUMBIA UNIVERSITY

As announced on 26 March 2018, Beroni Group (NSX: BTG) (“Beroni Group” or “the Company”) has entered into an agreement (“Sponsored Research Agreement”) with Columbia University in New York (“Columbia University”), to provide US\$1 million funding to a 12-month research program, under the direction of Professor W. Ian Lipkin, in the field of CII-ArboViroPlex rRT-PCR Test, a multiplex assay that can simultaneously test for Zika virus, all dengue virus serotypes, Chikungunya virus and West Nile virus.

Approval for Emergency Use by US FDA

In August 2017, the US Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for emergency use of the CII-ArboViroPlex rRT-PCR assay for the qualitative detection and differentiation of RNA from Zika virus, dengue virus, chikungunya virus, and West Nile virus in serum, and for the qualitative detection of Zika virus RNA in urine. Under the EUA, Columbia University and its authorized distributors may make the CII-ArboViroPlex rRT-PCR assay, with authorized labelling, available to certain authorized U.S. laboratories to perform the assays on samples from individuals meeting certain clinical or epidemiological criteria.

International PCT Application

Columbia University has previously filed the international application to preserve the right to obtain patent protection for the CII-ArboViroPlex rRT-PCR assay in all Patent Cooperation Treaty (“PCT”) member countries. This application is now approaching the “30-month deadline” for entry into the national phase, which means that the applicant must comply with the requirements of each individual country or territory of interest to the applicant. Under the Sponsored Research Agreement, Beroni Group has the option of obtaining an exclusive license in the territory of China.

Latest Developments

Beroni Group is pleased to advise that it has been working with Columbia University to secure the distribution rights to the US market for the distribution of the CII-ArboViroPlex rRT-PCR assay to authorised US laboratories. At the same time, it is also engaging with Columbia University with regard to the filing of the corresponding national patent applications for the CII-ArboViroPlex rRT-PCR assay in the designated PCT member countries. Beroni has requested Columbia University enter into national phase applications for 6 countries namely Australia, USA, China, Japan, India, and Saudi Arabia.

For further information please contact:

Mr Jacky Zhang

Executive Chairman

Tel: +86 1851 6931 911

E: 1710426553@qq.com

Mr Peter Wong

Executive Director and CFO

Tel: +61 423 727 580

E: pwong@asiainvest.com.au

About Beroni Group Limited (NSX:BTG)

Beroni Group is a Chinese biotechnological company which is dual listed on the National Stock Exchange of Australia. Its business mainly focuses on biotechnology, life sciences, environmental science and governance, precision medicine, regenerative medicine, and stem cell anti-cancer and anti-aging projects. Beroni Group's overall strategic goal is to have a global presence in the biotechnology, bio-science and environmental science industries.